Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT03996850

SPECT/CT for the Characterization of Renal Masses

SPECT/CT for the Characterization of Renal Masses: Impact on Clinical Decision Making

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
102 (actual)
Sponsor
Jonsson Comprehensive Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a less invasive way to check for kidney tumors.

Detailed description

PRIMARY OBJECTIVES: I. To determine the impact of technetium Tc-99m sestamibi (MIBI) SPECT/CT on patient management decisions. SECONDARY OBJECTIVES: I. To evaluate the impact of MIBI SPECT/CT on patient management decisions for tumors 1.5-3.0 cm and 3.1-5.0 cm. II. To assess the impact of MIBI SPECT/CT on decisional conflict score. III. To assess the impact of MIBI SPECT/CT on physician management recommendation. IV. To evaluate the sensitivity and specificity of MIBI SPECT/CT for the identification of an oncocytic renal mass (oncocytoma, chromophobe, and hybrid oncocytic tumor) with respect to tumor histology identified by renal mass biopsy or surgical resection. V. To compare the specificity of MIBI SPECT/CT with conventional cross-sectional imaging in predicting an oncocytic renal mass. VI. To assess the correlation between MIBI SPECT/CT outcomes to final treatment decisions. EXPLORATORY OBJECTIVES: I. Evaluate the mitochondria content in tumors that had positive MIBI SPECT/CT findings. OUTLINE: Patients receive technetium Tc-99m sestamibi intravenously (IV) then undergo SPECT/CT. After completion of study, patients are followed up for 6 months.

Conditions

Interventions

TypeNameDescription
PROCEDUREComputed TomographyUndergo SPECT/CT
OTHERQuestionnaire AdministrationAncillary studies
PROCEDURESingle Photon Emission Computed TomographyUndergo SPECT/CT
RADIATIONTechnetium Tc-99m SestamibiGiven IV

Timeline

Start date
2018-12-07
Primary completion
2025-03-03
Completion
2027-12-31
First posted
2019-06-25
Last updated
2026-03-13

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03996850. Inclusion in this directory is not an endorsement.